Longeveron Inc. LGVN
We take great care to ensure that the data presented and summarized in this overview for Longeveron Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in LGVN
Top Purchases
Top Sells
About LGVN
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
Insider Transactions at LGVN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 01
2024
|
Mohamed Wa'El Ahmed Hashad Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
13,357
-4.58%
|
$13,357
$1.88 P/Share
|
|
Oct 01
2024
|
Paul T Lehr General Counsel, Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
990
-0.62%
|
$990
$1.88 P/Share
|
|
Oct 01
2024
|
Nataliya Agafonova Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,316
-3.26%
|
$5,316
$1.88 P/Share
|
|
Oct 01
2024
|
Lisa Locklear Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,316
-3.25%
|
$5,316
$1.88 P/Share
|
|
Aug 15
2024
|
Neil E Hare |
BUY
Grant, award, or other acquisition
|
Direct |
23,500
+44.46%
|
-
|
|
Aug 15
2024
|
Rock Soffer |
BUY
Grant, award, or other acquisition
|
Direct |
23,500
+9.2%
|
-
|
|
Aug 15
2024
|
Ursula Ungaro |
BUY
Grant, award, or other acquisition
|
Direct |
23,500
+49.47%
|
-
|
|
Aug 15
2024
|
Khoso Baluch |
BUY
Grant, award, or other acquisition
|
Direct |
23,500
+37.98%
|
-
|
|
Aug 15
2024
|
Joshua Hare Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
93,766
+11.42%
|
-
|
|
Aug 15
2024
|
Paul T Lehr General Counsel, Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
31,505
-9.84%
|
$63,010
$2.46 P/Share
|
|
Aug 15
2024
|
Paul T Lehr General Counsel, Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
178,133
+35.74%
|
-
|
|
Aug 15
2024
|
Mohamed Wa'El Ahmed Hashad Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
39,248
-30.28%
|
$78,496
$2.46 P/Share
|
|
Aug 15
2024
|
Mohamed Wa'El Ahmed Hashad Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
311,250
+48.47%
|
-
|
|
Aug 15
2024
|
Lisa Locklear Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
14,035
-7.9%
|
$28,070
$2.46 P/Share
|
|
Aug 15
2024
|
Lisa Locklear Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
174,750
+49.59%
|
-
|
|
Aug 15
2024
|
Nataliya Agafonova Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
14,391
-8.11%
|
$28,782
$2.46 P/Share
|
|
Aug 15
2024
|
Nataliya Agafonova Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
175,750
+49.75%
|
-
|
|
Jul 02
2024
|
Neha J. Motwani |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+50.0%
|
$16,000
$1.68 P/Share
|
|
Jul 02
2024
|
Roger Joseph Hajjar |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+50.0%
|
$16,000
$1.68 P/Share
|
|
Jul 01
2024
|
Lisa Locklear Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
357
-10.91%
|
$357
$1.57 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.16M shares |
|---|---|
| Open market or private purchase | 323K shares |
| Payment of exercise price or tax liability | 172K shares |
|---|